Title: Pharmacologic management of overactive bladder.
Abstract: Overactive bladder (OAB) is a prevalent and costly condition that can affect any age group. Typical symptoms include urinary urgency, frequency, incontinence and nocturia. OAB occurs as a result of abnormal contractions of the bladder detrusor muscle caused by the stimulation of certain muscarinic receptors. Therefore, antimuscarinic agents have long been considered the mainstay of pharmacologic treatment for OAB. Currently, there are five such agents approved for the management of OAB in the United States: oxybutynin, tolterodine, trospium, solifenacin and darifenacin. This article summarizes the efficacy, contraindications, precautions, dosing and common side effects of these agents. All available clinical trials on trospium, solifenacin and darifenacin were reviewed to determine its place in therapy.
Publication Year: 2007
Publication Date: 2007-01-01
Language: en
Type: article
Indexed In: ['doaj', 'pubmed']
Access and Citation
Cited By Count: 28
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot